Director at Immunic (IMUX) gets options at $10.12 a share

Immunic (IMUX) granted director Robert Thorvald Nagel 25,370 stock options at $10.12 per share. The options vest monthly over one year and expire in 2036. The economic benefits will be transferred to BVF Partners L.P.

Original reporting
Published Sep 19, 2026, 1:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 9:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$IMUX
Neutral
high confidence
Mentioned
$IMUX
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$IMUXNeutralLow
01

Why it matters

The grant is a routine compensation event with negligible market impact.

02

Market read

Low relevance; primarily of interest to existing shareholders and compliance monitors.

03

What to watch

Potential future insider buying pressure if the director later acquires shares beyond the option grant.

Relevance 4/10Novelty 3/10Timing: post‑grant disclosure

Background

Immunic filed a Form 4 reporting a director's stock option grant.

Company-level read

Ticker impact

$IMUXNeutralHigh confidence
Context

Director Robert Thorvald Nagel was granted 25,370 stock options at $10.12 per share, vesting monthly over one year.

Expected impact

minimal effect on share price

Evidence & confidence

The grant size is tiny relative to float and the exercise price is near current market levels, so traders are unlikely to act.

Market effects

None; the grant does not affect the biotech sector broadly.

No regional impact expected.

Limited to Immunic shareholders.

Counterpoint

If the director plans to exercise and sell, a slight upside could emerge if the stock rallies above $10.12.

Key entities

  • Robert Thorvald Nagel

    Recipient of the option grant.

  • BVF Partners L.P.

    Entity to receive any economic benefit from the options.

Related articles

$IMUXMedAI 8/10

Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

IMMUNIC, INC. (IMUX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update – Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 – – Initiatio

Med

Immunic Releases Q3 2026 Financial Results

Immunic Inc. reported a narrower Q3 2026 loss of $0.99 per share, down 25% from the prior year. The biotech company's net loss was $42.3M, attributed to R&D investments. Analysts remain bullish, with 9 buy and 1 hold rating. The company is developing therapies for chronic inflammatory and autoimmune diseases.

$IMUXMed

Immunic 3Q 2026: EPS ($0.99) — 10-Q Summary

Immunic reported a net loss of $42.3M, up 65% YoY, with operating expenses rising 67%. R&D costs increased 20%, while G&A expenses surged 225% due to personnel costs. Top-line data from Phase 3 trials is expected in December 2026. According to the company, Phase 3 progressive MS trial initiation is ongoing, with first-patient-enrolled expected in the first half of 2027.

$IMUXHigh

Immunic shares fall 5% on third quarter earnings miss

Immunic Inc. (IMUX) reported a Q3 loss of $0.99 per share, missing estimates by $0.05. Shares fell 5.44% premarket. Net loss was $42.3M, up from $25.6M last year, due to higher operating expenses. The company expects top-line data from ENSURE-1 and ENSURE-2 trials in December 2026. Cash reserves are $132.0M, expected to last into late 2027.